
Alnylam management said it now expects full-year TTR product sales to land at the low end of its $4.2 billion to $4.5 billion range.
ALNY is down 25.13% today. Volume is 11.80M vs a 30-day average of 1.36M (8.69x).
Alnylam Pharmaceuticals, Inc. is scheduled to report earnings Today · before open. Analysts expect EPS of $1.65 on revenue of about $1.46B. Stocks often move sharply on earnings day.

Alnylam management said it now expects full-year TTR product sales to land at the low end of its $4.2 billion to $4.5 billion range.

AMVUTTRA revenue jumped 65% year over year as TTR franchise momentum accelerates.

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported third-quarter 2026 global net product revenue of approximately $1.3 billion, up 52% from a year earlier and 10% sequentially, as gro…

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDTCompany ParticipantsJoshua Brodsky - Vice President of Investor...

Premarket movers on Oct. 29, 2026 include NCPL, PCLA, INLF, NUWE, BURU, INSM, CROX, GKOS, MAX, PRCH, IOVA, XRX, FTNT, SFM, TWI, ALNY and NOW.